At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 149 enrolled
Drug / intervention
Rosiglitazone (BRL49653C)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Rosiglitazone Maleate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Combination Therapy With Sulfonyl Urea) - A Placebo-Controlled Double-Blind Study -
In Brief
A Phase 3 clinical trial evaluating Rosiglitazone (BRL49653C) for Diabetes Mellitus, Type 2. Completed, enrolled 149 participants across 4 sites.
Detailed Summary
This study was designed to compare the efficacy and safety of BRL49653C versus placebo with concomitant use of sulfonyl urea (SU).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
Countries, Japan
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2006
First PostedFeb 2007
Primary CompletionMar 2007
TodayJul 2026
First PostedFeb 8, 2007
Enrollment StartMay 24, 2006
Primary CompletionMar 28, 2007
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 19.4 years ago
Interventions
Rosiglitazone (BRL49653C)drug
study drug